Reinventing How Pharma Provides HCPs with Access to Medical Information

Pharmaceutical and healthcare organizations are consistently challenged with meeting the digital needs of healthcare workers while adhering to the needs of a rigorous legal and regulatory environment. We understand that balance and have navigated these constraints, ensuring that medical/legal compliance is met while providing the optimal user experience. We’ve introduced unique features such as mobile accessibility to content, the ability to create and save personal libraries of information, 多媒体内容的整合, and the ability to search for medical information across a wide range of clinical scenarios—all while meeting regulatory requirements and speeding up the review and publication process.

Legacy Medical Information systems often haven’t considered how HCPs use the information, 他们需求的紧迫性, or the tools they use to access sites and content. We come to the table with a fundamental understanding of how clinicians work. Our research process uncovers unique findings around how they interact with biopharma brands, access information specific to a brand’s products, and the environments in which they need access to that information.

We’ve worked with organizations across business functions to understand the ins and outs—and, 最重要的是, 内容创造的“原因”, 批准, 在一个受监管的行业出版. This had allowed us to articulate what is necessary, 什么是遗产?, and what is just misalignment between content creators and content approvers. We’ve aligned all teams on a common goal: to help HCPs make the right prescribing decisions for their patients in any situation. We’ve worked with biopharma partners towards building trust between teams by mediating discussions and facilitating all-hands workshops, 在其他活动中.

Transitioning to a digital-first approach to content creation has given our partners an opportunity to rethink how content is presented. A comprehensive content strategy with a predictable content model guides the creation of more useful information for HCPs.

One of the most important steps we’ve taken with biopharmaceutical organizations is establishing a governance framework to support these models and templates. 作为这个过程的一部分, companies have also built content guardrails that foster consistency across brands and ensure compliance. Together we have saved content creators and approvers countless hours by optimizing this process and enforcing guidelines that remove subjectivity. These organizations have reduced their review cycles by as much as 50% with a predictable design and content model in place, allowing reviewers to focus on new strategic opportunities.